The next-generation sequencing of cfDNA using a targeted four-gene panel (CTNNB1, K-ras, PTEN and PIK3CA) identified mutations within the plasma that matched those within the corresponding endometrial tumour in 33% of women, although this could only detect 18% of mutations in women with early-stage disease [51]. Here, KRAS is linked to endometrium neoplasm.